Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.11, while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IEMG | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $6.79 |
52-Week Low | $61.76 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.02, up 1.84% today with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% returns over the past year, driven by emerging market exposure and a 40% technology weighting focused on AI themes. Recent news highlights IEMG's outperformance versus developed market ETFs and its competitive 0.09% expense ratio.
Outlook remains positive given emerging market growth potential and AI-driven tech exposure, though risks include concentration in volatile emerging economies and elevated RSI levels suggesting potential near-term consolidation. The ETF's valuation discount to US equities and strong institutional inflows support continued investor interest.
RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.
The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
